Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.

Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A.

J Clin Endocrinol Metab. 2012 Feb;97(2):E213-7. doi: 10.1210/jc.2011-2882. Epub 2012 Jan 11.

PMID:
22238393
2.

Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.

Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J.

J Clin Endocrinol Metab. 2012 Feb;97(2):416-25. doi: 10.1210/jc.2011-1995. Epub 2012 Jan 11.

PMID:
22238382
3.

Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics.

Albertsson-Wikland K, Mårtensson A, Sävendahl L, Niklasson A, Bang P, Dahlgren J, Gustafsson J, Kriström B, Norgren S, Pehrsson NG, Odén A.

J Clin Endocrinol Metab. 2016 May;101(5):2149-59. doi: 10.1210/jc.2015-3951. Epub 2016 Feb 26.

PMID:
26918292
4.

Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.

Ross JL, Lee PA, Gut R, Germak J.

Growth Horm IGF Res. 2015 Dec;25(6):286-93. doi: 10.1016/j.ghir.2015.08.006. Epub 2015 Aug 22.

PMID:
26363846
5.

Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone.

Swerdlow AJ, Cooke R, Albertsson-Wikland K, Borgström B, Butler G, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Gausche R, Giacomozzi C, Kiess W, Hokken-Koelega AC, Kuehni CE, Landier F, Maes M, Mullis PE, Pfaffle R, Sävendahl L, Sommer G, Thomas M, Tollerfield S, Zandwijken GR, Carel JC.

Horm Res Paediatr. 2015;84(3):172-83. doi: 10.1159/000435856. Epub 2015 Jul 23.

6.

Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.

Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, Cowell CT, Werther G, Cotterill A, Davies PS; Australasian Paediatric Endocrine Group (APEG).

Clin Endocrinol (Oxf). 2012 Jul;77(1):62-71. doi: 10.1111/j.1365-2265.2011.04230.x.

PMID:
21950731
8.

Update in mortality in GH-treated patients.

Erfurth EM.

J Clin Endocrinol Metab. 2013 Nov;98(11):4219-26. doi: 10.1210/jc.2013-2415. Epub 2013 Sep 12. Review.

PMID:
24030944
9.

Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.

Quigley CA, Child CJ, Zimmermann AG, Rosenfeld RG, Robison LL, Blum WF.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3195-3205. doi: 10.1210/jc.2017-00214.

PMID:
28575299
11.

Growth hormone replacement does not increase mortality in patients with childhood-onset growth hormone deficiency.

Berglund A, Gravholt CH, Olsen MS, Christiansen JS, Stochholm K.

Clin Endocrinol (Oxf). 2015 Nov;83(5):677-83. doi: 10.1111/cen.12848. Epub 2015 Aug 3.

PMID:
26147754
12.

Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.

Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, Lippe B.

J Clin Endocrinol Metab. 2005 Sep;90(9):5247-53. Epub 2005 Jul 5.

PMID:
15998780
15.

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study.

Blankenstein O, Snajderova M, Blair J, Pournara E, Pedersen BT, Petit IO.

Eur J Endocrinol. 2017 Aug;177(2):145-155. doi: 10.1530/EJE-16-1055. Epub 2017 May 18.

16.

Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood.

Poidvin A, Weill A, Ecosse E, Coste J, Carel JC.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1291-1298. doi: 10.1210/jc.2016-3145.

PMID:
28324032
17.

GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.

Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC.

Clin Endocrinol (Oxf). 2003 Dec;59(6):779-87.

PMID:
14974922
18.

Safety of growth hormone treatment in pediatric patients with idiopathic short stature.

Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, Ross JL, Cassorla FG, Wolka AM, Wit JM, Rekers-Mombarg LT, Cutler GB Jr.

J Clin Endocrinol Metab. 2005 Sep;90(9):5188-96. Epub 2005 May 17.

PMID:
15899952
19.

Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.

de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG.

J Clin Endocrinol Metab. 1999 May;84(5):1558-61.

PMID:
10323379
20.

Hormone replacement therapy in children: The use of growth hormone and IGF-I.

Pfäffle R.

Best Pract Res Clin Endocrinol Metab. 2015 Jun;29(3):339-52. doi: 10.1016/j.beem.2015.04.009. Epub 2015 Apr 29. Review.

PMID:
26051295

Supplemental Content

Support Center